IDEXX Laboratories, Inc. vs Magnolia Oil & Gas Corporation Class A Common Stock — how do they compare? IDEXX Laboratories, Inc. trades at $532.96 (market cap $40.99B), while Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.9 (market cap $6.76B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.1× Magnolia Oil & Gas Corporation Class A Common Stock's market cap, and Magnolia Oil & Gas Corporation Class A Common Stock pays a 2.63% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days on average.
| IDXX | MGY | |
|---|---|---|
Market Cap | $40.99B | $6.76B |
Volume | 445,410 | 2,815,157 |
Sector | Health | Energy |
52-Week High | $766.68 | $32.36 |
52-Week Low | $504.70 | $21.24 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $41.89B | $6.88B |
Dividend Yield | — | 2.63% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $529.01, up 0.97% with strong fundamental performance including 25.03% net income margin and consistent earnings beats. The stock shows neutral technical signals with support at $518 and resistance at $528. Recent acquisitions like CoVetAI and diagnostic platform expansions demonstrate strategic growth initiatives. Revenue grew from $3.9B in 2024 to $4.3B in 2025 with profit margins expanding to 24.61%.
Outlook remains positive with 56.5% analyst buy ratings and $665 consensus price target representing 25.7% upside. Key risks include FX headwinds and weaker U.S. vet visits, but strong recurring revenue and diagnostic innovation pipeline support long-term growth framework. The company's premium valuation (P/E 36.56) reflects market confidence in sustained profitability.
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →